Syros Pharmaceuticals Inc. Is Being Inquired Into For Possibly Violating Securities Laws And Impacted Investors Are Urged To Contact The Schall Law FirmAccesswire • 09/03/24
Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Against Syros Pharmaceuticals, Inc. (SYRS) and Encourages Stockholders to Seek Compensation for Alleged WrongdoingsAccesswire • 09/03/24
The Schall Law Firm Invites Public Participation In An Investigation Into Whether Syros Pharmaceuticals Inc Committed Securities FraudAccesswire • 09/02/24
Bronstein, Gewirtz and Grossman, LLC Initiates an Investigation into Allegations Against Syros Pharmaceuticals, Inc. (SYRS) And Encourages Investors to Reach OutAccesswire • 09/02/24
Syros Pharmaceuticals Inc. May Have Infringed On Shareholders' Rights And Those With Losses Are Urged To Contact The Schall Law FirmAccesswire • 09/01/24
Bronstein, Gewirtz and Grossman, LLC Encourages Syros Pharmaceuticals, Inc. (SYRS) Investors to Inquire about Securities InvestigationAccesswire • 09/01/24
The Schall Law Firm Is Looking Into Whether Syros Pharmaceuticals Is Liable To Stockholders For Breaking Securities Laws And The Firm Wants The Public's HelpAccesswire • 08/30/24
Individuals With Losses In Syros Pharmaceuticals Inc. Should Join The Schall Law Firm In An Inquiry Into Possible Securities Law ViolationsAccesswire • 08/30/24
Bronstein, Gewirtz and Grossman, LLC Encourages Syros Pharmaceuticals, Inc. (SYRS) Shareholders to Inquire about Securities InvestigationAccesswire • 08/30/24
Stockholders In Syros Pharmaceutical Inc. Are Invited To Join The Schall Law Firm In An Inquiry About Possible Securities Law InfractionsAccesswire • 08/29/24
Bronstein, Gewirtz and Grossman, LLC Encourages Syros Pharmaceuticals, Inc. (SYRS) Stockholders to Inquire about Securities InvestigationAccesswire • 08/29/24
Syros Pharmaceuticals Being Investigated on Behalf of Syros Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details.Accesswire • 08/29/24
Syros Pharmaceutical Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Shareholders To Reach OutAccesswire • 08/28/24
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAccesswire • 08/28/24
SYRS ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Syros Pharmaceuticals, Inc. Shareholders Who Lost MoneyAccesswire • 08/28/24
The Schall Law Firm Is Looking Into Syros Pharmaceuticals Inc's Potential Violations Of Securities Laws And Investors Are Invited To ContributeAccesswire • 08/27/24
Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Against Syros Pharmaceuticals, Inc. (SYRS) and Encourages Shareholders to Seek Compensation for Alleged WrongdoingsAccesswire • 08/27/24
Shareholders that lost money on Syros Pharmaceuticals, Inc.(SYRS) should contact Levi & Korsinsky about Securities Fraud Investigation - SYRSAccesswire • 08/27/24
Syros Pharmaceuticals to Present at Upcoming Medical and Investor ConferencesBusiness Wire • 08/27/24
A Securities Fraud Inquiry Has Been Opened Into Syros Pharmaceuticals Inc And The Schall Law Firm Wants Stockholders To JoinAccesswire • 08/26/24
Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Against Syros Pharmaceuticals, Inc. (SYRS) and Encourages Investors to Seek Compensation for Alleged WrongdoingsAccesswire • 08/26/24
Levi & Korsinsky Reminds Syros Pharmaceuticals Investors of the Ongoing Investigation into Potential Violations of Securities Laws - SYRSAccesswire • 08/25/24
ATTENTION SYRS SHAREHOLDERS: Investors who lost money on Syros Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigationAccesswire • 08/25/24
Syros Pharmaceuticals Inc Is Being Investigated By The Schall Law Firm For Possible Violations Of Securities Laws And Investors Are Invited To Reach OutAccesswire • 08/25/24
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Stockholders to Seek Compensation for Alleged WrongdoingsAccesswire • 08/25/24